Can NBIX's Q2 Beat and Higher Ingrezza Guidance Drive More Growth?
Neurocrine Biosciences (NBIX) exceeded Q2 expectations with strong revenue and adjusted EPS, largely driven by its flagship therapy Ingrezza, for which the company also raised its 2026 sales outlook. While newer products like Crenessity and Vykat XR are broadening the portfolio, Ingrezza remains the primary revenue driver, prompting increased research and commercial spending. The company's future growth hinges on maintaining prescription momentum and successful product launches, balanced against rising operational costs.
Neurocrine Biosciences (NBIX) Could Be 28% Undervalued On Fresh INGREZZA Data
Neurocrine Biosciences (NBIX) is potentially 28% undervalued according to a recent analysis, following positive KINECT-PRO Phase 4 results for its drug INGREZZA. Despite a recent share price dip, NBIX has shown strong long-term returns and has a diverse CNS pipeline, suggesting significant future growth potential. However, the valuation hinges on successful execution for INGREZZA and CRENESSITY, with risks from pricing pressure and higher SG&A.
Neurocrine Biosciences (NBIX) Could Be 28% Undervalued On Fresh INGREZZA Data
Neurocrine Biosciences (NBIX) has released new KINECT-PRO Phase 4 results for INGREZZA, showing sustained improvements in tardive dyskinesia symptoms and patient quality of life. Despite recent share price fluctuations, the company is seen as significantly undervalued by analysts, trading at a 27.5% discount to a fair value estimate of $213 per share. This valuation is supported by a robust CNS pipeline and ongoing innovation, though execution risks for INGREZZA and CRENESSITY, along with pricing pressures, remain potential challenges.
NBIX Stock Dips 12% in a Month: Time to Buy, Hold or Sell?
Neurocrine Biosciences (NBIX) stock has declined by 12% over the past month, despite strong Q2 2026 earnings, primarily due to safety concerns surrounding its newly acquired drug, Vykat XR. While Ingrezza remains a key revenue driver with strong growth, and Crenessity is rapidly expanding, the competitive landscape and pipeline execution risks suggest a "wait-and-watch" approach for investors until there's clearer visibility on Vykat XR's safety and commercial trajectory.
14,787 Shares in Neurocrine Biosciences, Inc. $NBIX Purchased by ABN AMRO Bank N.V.
ABN AMRO Bank N.V. has purchased 14,787 shares of Neurocrine Biosciences (NASDAQ:NBIX), valued at approximately $2.51 million, during the second quarter. Other institutional investors have also adjusted their holdings in the company, with 92.59% of the stock owned by hedge funds and institutions. The stock holds a "Moderate Buy" consensus rating from analysts with an average price target of $200.86, despite recent insider sales totaling nearly $59.5 million.
Can Neurocrine (NBIX) Turn Patient-Centric INGREZZA Data Into Durable Neurology Leadership?
Neurocrine Biosciences recently released positive Phase 4 KINECT-PRO results for INGREZZA, showing improved patient-reported quality of life and reduced tardive dyskinesia severity. While these findings strengthen INGREZZA's clinical profile, the company's investment narrative still hinges on volume growth amid payer scrutiny and its efforts to diversify its portfolio beyond movement disorders. Investors should consider the potential impact of pricing pressure on INGREZZA's future profitability.
S&CO Inc. Makes New Investment in Neurocrine Biosciences, Inc. $NBIX
S&CO Inc. has acquired a new stake in Neurocrine Biosciences, purchasing 7,000 shares valued at approximately $1.18 million during the second quarter. Institutional investors collectively own 92.59% of NBIX, and analysts maintain a "Moderate Buy" rating with an average price target of $200.86. Despite significant insider selling over the past 90 days, the company's stock has seen a 1.3% increase.
Focus Partners Advisor Solutions LLC Invests $1.93 Million in Neurocrine Biosciences, Inc. $NBIX
Focus Partners Advisor Solutions LLC has invested $1.93 million in Neurocrine Biosciences, Inc. by purchasing 11,434 shares in the second quarter. Institutional investors hold 92.59% of NBIX shares, while company insiders have sold a significant amount of stock recently. Analysts maintain a "Moderate Buy" rating with an average price target of $200.86, against the stock's recent opening price of $152.72.
Can Neurocrine (NBIX) Turn Patient-Centric INGREZZA Data Into Durable Neurology Leadership?
Neurocrine Biosciences' INGREZZA showed positive Phase 4 results, improving patient-reported quality of life and tardive dyskinesia severity. The company aims to leverage this patient-centric data to solidify INGREZZA's leadership in neurology, while also working to diversify its portfolio beyond movement disorders and manage potential pricing pressures. Analysts project significant revenue and earnings growth for Neurocrine by 2029, suggesting a potential upside to its current stock price.
Summit Global Investments Invests $4.96 Million in Neurocrine Biosciences, Inc. $NBIX
Summit Global Investments recently acquired a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX), purchasing 29,424 shares valued at approximately $4.96 million during the second quarter. This move is part of broader institutional investor activity, with several other hedge funds also adjusting their positions in NBIX. Wall Street analysts have largely issued "buy" ratings for Neurocrine Biosciences, with a consensus "Moderate Buy" and an average target price of $200.86.
Cutting-edge drug quells insatiable desire to eat. Experts warn it could be tied to deaths
Neurocrine's drug, Vykat XR, designed to treat the insatiable appetite associated with Prader-Willi Syndrome (PWS), is facing safety warnings following seven deaths. Patient organizations and doctors are calling for more research into the drug's safety, emphasizing that PWS patients often have multiple other health issues.
Deutsche Bank Adjusts Neurocrine Biosciences PT to $165 From $190, Maintains Hold Rating
Deutsche Bank has adjusted its price target for Neurocrine Biosciences (NBIX) to $165, down from $190, while maintaining a Hold rating on the stock. This adjustment comes amidst recent news including positive Phase 4 study results for Ingrezza capsules and the initiation of a Phase 1 trial for an obesity drug candidate. The company also reported strong Q2 2026 earnings, surpassing revenue and adjusted EPS estimates.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Consensus Rating of "Moderate Buy" by Brokerages
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has received a consensus "Moderate Buy" rating from twenty-four brokerages, with an average 12-month price target of $201.50. The company's stock opened at $156.49, has a market capitalization of $15.91 billion, and has seen significant insider selling totaling over $61 million in the last quarter, while institutional investors hold 92.59% of the shares. Analysts from Wells Fargo, JPMorgan Chase, Wedbush, and Guggenheim have recently updated their price targets and ratings, generally maintaining an "overweight" or "outperform" stance.
Why Neurocrine Biosciences (NBIX) Stock Is Down Today
Neurocrine Biosciences (NBIX) stock is down 3.1% today, likely due to investor profit-taking and a reset of expectations following its late-July earnings release. While the company reported strong revenue growth and increased INGREZZA sales guidance, it also raised spending outlooks and highlighted the balance-sheet impact of its Soleno acquisition, leading to market concerns about future margins and capital allocation. Insider trading activity shows numerous sales by executives, while institutional investors have mixed views, with some significantly increasing their holdings and others decreasing them.
What's Going On With Neurocrine Biosciences Stock On Wednesday?
Neurocrine Biosciences stock experienced a dip after reports emerged of deaths and severe complications potentially linked to its drug Vykat XR, used for Prader-Willi syndrome. The FDA's adverse event data revealed seven deaths and over 100 serious events, primarily involving edema, respiratory, and cardiac issues, though a direct causal link hasn't been definitively proven. Healthcare providers are advised to conduct thorough assessments and monitor patients closely when prescribing Vykat XR.
Deaths reported after treatment with Neurocrine’s approved Prader-Willi drug
Reports have emerged of seven deaths and 100 serious adverse events potentially linked to Neurocrine Biosciences’ Prader-Willi syndrome drug, Vykat, prompting concerns among clinicians and patient advocacy groups. Concurrently, Aardvark Therapeutics terminated its Phase 3 trial for ARD-101 for the same condition due to cardiac safety signals. While the events concerning Vykat are under investigation and causality is not yet established, both developments highlight the challenges in treating this rare genetic disease and could impact the commercial trajectory of these therapies.
Prader-Willi experts flag safety risks linked to Neurocrine's rare disease drug
Experts in Prader-Willi Syndrome have raised safety concerns regarding Neurocrine's drug Vykat XR, citing serious adverse events reported in patients. Post-marketing surveillance revealed reports of edema, respiratory and cardiac complications, and seven deaths linked to the drug as of July 31st, though no causal link has been established. Neurocrine, which acquired Soleno for access to Vykat XR, stated the drug has a compelling risk-benefit profile and is working with the FDA and patient advocacy groups to assess all available data.
Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia
Neurocrine Biosciences announced the publication of KINECT-PRO™ Phase 4 study results, showing that INGREZZA® (valbenazine) capsules significantly improved patient-reported quality of life and daily functioning, alongside clinician-rated tardive dyskinesia (TD) movement severity. These improvements were seen across various patient demographics, including those with mild TD, and were sustained over 24 weeks. The study highlights the drug's positive impact on patients' daily lives and symptoms, reinforcing its broad benefit regardless of underlying psychiatric diagnosis or baseline movement severity.
Neurocrine slips on safety issues linked to Vykat XR (NBIX:NASDAQ)
Neurocrine Biosciences' shares fell following resurfacing safety concerns related to Vykat XR, a rare disease therapy acquired through Soleno Therapeutics. Reports of potential fatalities and severe side effects, such as edema, have been linked to the drug, though a definitive causal link has not yet been established. Neurocrine is collaborating with the FDA, prescribers, and advocacy groups to monitor the drug's safety.
Handelsbanken Fonder AB Has $34.70 Million Holdings in Neurocrine Biosciences, Inc. $NBIX
Handelsbanken Fonder AB increased its stake in Neurocrine Biosciences (NASDAQ:NBIX) by 9.6% in the second quarter, now holding 205,871 shares valued at $34.7 million. Institutional investors collectively own 92.59% of the company, which has a market capitalization of $16.46 billion. Analysts generally rate NBIX as a "Moderate Buy" with an average price target of $201.50, despite recent insider stock sales totaling $61.9 million.
Neurocrine Biosciences rare disease drug possibly tied to safety issues, experts say
A group of physicians and experts in Prader-Willi syndrome has notified clinicians about a series of patient deaths and severe side effects potentially linked to Neurocrine Biosciences' newly approved drug, Vykat XR. Approved in March 2025, Vykat XR is intended to manage intense hunger in Prader-Willi syndrome patients. Since its approval, seven deaths and over 100 serious adverse events, including hospitalizations for swelling, respiratory, and heart complications, have been reported to the FDA, prompting experts to raise awareness despite no definitive link to the drug yet.
Is Neurocrine Biosciences (NBIX) Fully Valued As It Enters Phase 1 Obesity Testing?
Neurocrine Biosciences (NBIX) has commenced a Phase 1 study for its obesity treatment candidate, NBIP 1968, following positive Q2 and H1 2026 financial results. Despite recent stock momentum and a current share price of $163.41, Simply Wall St's analysis suggests the company might be undervalued with a fair value of $213, driven by its robust CNS pipeline and internal innovation. The valuation hinges on continued revenue growth, margin expansion, and the successful progression of its pipeline, while potential risks include payer pushback on INGREZZA pricing and trial disappointments.
Is Neurocrine Biosciences (NBIX) Fully Valued As It Enters Phase 1 Obesity Testing?
Neurocrine Biosciences (NBIX) is entering Phase 1 testing for an obesity treatment while also reporting higher Q2 2026 revenues and earnings. Despite a strong historical share price performance, the stock is considered 23.3% undervalued by many, with a fair value estimated at $213 per share. The valuation is supported by its diversified CNS pipeline and ongoing innovation in biologics, though risks like payer pushback on pricing or trial disappointments exist.
Neurocrine begins Phase I trial of NBIP-‘1968 triple agonist for obesity
Neurocrine Biosciences has initiated a Phase I clinical study for NBIP-‘1968, a triple agonist targeting GLP-1, GIP, and glucagon receptors, as a potential obesity treatment. The trial will assess the safety and tolerability of single ascending doses in overweight or obese adults. This investigational drug is designed for once-weekly subcutaneous injection and is part of Neurocrine's broader obesity development program, which also includes NBIP-‘2118, another Phase I asset.
Bank of America Corp DE Boosts Holdings in Neurocrine Biosciences, Inc. $NBIX
Bank of America Corp DE increased its stake in Neurocrine Biosciences, Inc. (NBIX) by 10.6% in the first quarter, holding over 583,000 shares worth about $76.9 million. Despite significant insider selling totaling over $62 million in the last quarter, institutional investors own 92.59% of the stock. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $201.50, suggesting potential upside from its current price.
Assenagon Asset Management S.A. Has $37.52 Million Holdings in Neurocrine Biosciences, Inc. $NBIX
Assenagon Asset Management S.A. significantly increased its stake in Neurocrine Biosciences, Inc. by 143.3% in the second quarter, bringing its total holdings to 222,606 shares valued at approximately $37.52 million. This move comes as institutional investors collectively own 92.59% of NBIX, and analysts maintain a "Moderate Buy" consensus rating with an average price target of $201.50. Despite positive analyst sentiment and institutional interest, Neurocrine insiders have sold a substantial amount of shares totaling $62.45 million over the past 90 days.
Neurocrine Biosciences, Inc. $NBIX Shares Purchased by Cetera Investment Advisers
Cetera Investment Advisers significantly increased its stake in Neurocrine Biosciences (NBIX) by 50.1% in the first quarter, now owning 20,245 shares valued at $2.67 million. Institutional investors hold 92.59% of NBIX. Despite insider sales totaling over $62 million in the past quarter, analysts maintain a "Moderate Buy" consensus with an average price target of $201.50 for the biopharmaceutical company.
Neurocrine Biosciences, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:NBIX) 2026-08-07
This article announces that Neurocrine Biosciences, Inc. (NBIX) has published its slide deck in conjunction with its Q2 2026 earnings call. The earnings call presentation was made on August 7, 2026. The article was written by the Seeking Alpha Transcripts team, which regularly publishes thousands of quarterly earnings call transcripts.
Neurocrine Biosciences, Inc. $NBIX Stake Boosted by PKO BP BANKOWY Universal Pension Society JSC
PKO BP BANKOWY Universal Pension Society JSC significantly increased its stake in Neurocrine Biosciences (NASDAQ:NBIX) by 23.1% in the second quarter, now holding 170,802 shares valued at $28.8 million. This move highlights continued institutional investor interest, with several other hedge funds also boosting their positions. Despite strong institutional backing and a "Moderate Buy" consensus rating from analysts, company insiders sold approximately $62.4 million worth of stock during the last quarter.
ETFs Investing in Neurocrine Biosciences, Inc. Stocks
This article lists various Exchange Traded Funds (ETFs) that hold stocks of Neurocrine Biosciences, Inc. The list, sorted by market value, provides details such as market value, weight, issuer, management style, expense ratio, assets under management (AUM), price, change, relative volume, and 3-year NAV total return for each ETF. These ETFs offer investors diversified opportunities to invest in Neurocrine Biosciences, Inc. with potentially lower risk.
How Stronger Q2 Results and New Equity Capacity Will Impact Neurocrine Biosciences (NBIX) Investors
Neurocrine Biosciences recently reported strong Q2 2026 results, with significant revenue and net income, alongside a new equity shelf registration tied to an ESOP offering. This dual development highlights the company's efforts to strengthen employee ownership and financial flexibility. The article discusses how these factors, coupled with ongoing challenges in drug pricing and reimbursement, shape Neurocrine's investment outlook and future growth expectations.
Neurocrine Biosciences, Inc. (NBIX) Stock Price, News, Quote & History
This Yahoo Finance page provides detailed stock information for Neurocrine Biosciences, Inc. (NBIX), including its current price, historical data, financial performance, analyst ratings, and company overview. It highlights key products like INGREZZA and several pipeline candidates for neurological and psychiatric disorders. The company's market performance, earnings trends, and comparative data with similar pharmaceutical firms are also presented.
Neurocrine Biosciences Begins Phase 1 Study of GLP-1/GIP/Glucagon Triple Agonist NBIP-'1968 for Obesity
Neurocrine Biosciences has initiated a Phase 1 clinical study for NBIP-'1968, a GLP-1/GIP/glucagon receptor triple agonist, as a treatment for obesity. This move signifies the company's entry into the multi-agonist incretin therapeutics market, aiming to address limitations of current GLP-1-based treatments such as gastrointestinal tolerability and lean muscle mass loss. NBIP-'1968 is designed for once-weekly subcutaneous administration, targeting multiple metabolic pathways to optimize benefits and tolerability.
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist
Neurocrine Biosciences has initiated a Phase 1 clinical study for NBIP-'1968, a GLP-1/GIP/glucagon receptor triple agonist, as a potential treatment for obesity. This investigational drug is designed for once-weekly subcutaneous administration and aims to target multiple metabolic pathways for appetite regulation, energy balance, and glycemic control. The study marks an important step in expanding Neurocrine's obesity portfolio, which includes other investigational compounds and earlier-stage programs focused on complementary mechanisms.
Neurocrine Biosciences (NBIX) CSO Jude Onyia makes bona fide stock gift
Jude Onyia, Chief Scientific Officer of Neurocrine Biosciences (NBIX), made a bona fide gift of 2,409 shares of common stock effective August 4, 2026. This transaction was a charitable contribution, not a market sale, and no value was received for the shares. After this gift, Onyia directly holds 20,996 shares of NBIX common stock.
Neurocrine Biosciences (NASDAQ:NBIX): A Value Stock With Quality Behind the Discount
Neurocrine Biosciences (NBIX) is presented as a compelling value stock due to its strong valuation score, profitability, and growth prospects despite trading at a higher-than-average P/E. The company boasts excellent financial health, a debt-free balance sheet, and impressive historical and projected EPS and revenue growth. While risks such as pipeline uncertainties and lack of dividends exist, NBIX's fundamentals suggest it's a solid opportunity for value-oriented investors.
Canaccord raises Neurocrine Bio price target on strong sales beat
Canaccord Genuity increased its price target for Neurocrine Biosciences Inc. (NASDAQ: NBIX) from $200 to $210, maintaining a Buy rating, following the company's strong second-quarter performance. Neurocrine's sales for Ingrezza and Crenessity significantly exceeded analyst estimates, contributing to a 34% revenue growth. The company also saw positive initial sales from its recent acquisition, Soleno Therapeutics, and its stock has risen substantially in 2026.
H.C. Wainwright reiterates Neurocrine Bio stock rating on pipeline progress
H.C. Wainwright has reiterated a Buy rating and a $215.00 price target for Neurocrine Biosciences (NASDAQ:NBIX), citing significant progress in its drug pipeline. The company affirmed upcoming Phase 3 data for osavampator in major depressive disorder and direclidine in schizophrenia, both of which showed promising results in earlier trials. This comes after strong second-quarter 2026 financial results, with earnings and revenue exceeding expectations, leading several other analyst firms to raise their price targets for NBIX.
Canaccord raises Neurocrine Bio price target on strong sales beat
Canaccord Genuity raised its price target on Neurocrine Biosciences (NASDAQ:NBIX) to $210 from $200, maintaining a Buy rating after the company's strong Q2 results. Sales
H.C. Wainwright reiterates Neurocrine Bio stock rating on pipeline progress By Investing.com
H.C. Wainwright has reaffirmed its Buy rating and $215.00 price target for Neurocrine Biosciences Inc. (NASDAQ: NBIX), citing the company's strong pipeline progress and financial performance. The company reported significant revenue growth and provided updates on its clinical trials for osavampator and direclidine, which are showing promising results for major depressive disorder and schizophrenia, respectively. This positive outlook is further supported by Neurocrine's impressive Q2 2026 earnings and increased guidance for Ingrezza sales.
Canaccord raises Neurocrine Bio price target on strong sales beat By Investing.com
Canaccord Genuity has increased its price target for Neurocrine Biosciences (NBIX) to $210 from $200, maintaining a Buy rating, after the company reported strong second-quarter results. Sales for its treatments Ingrezza and Crenessity significantly exceeded analyst estimates, contributing to a 34% revenue growth over the past twelve months. The firm views Neurocrine as undervalued, with further catalysts expected from its pipeline in 2027 and beyond.
Is Neurocrine Biosciences (NBIX) A Bargain After Strong Q2 Results And Higher Guidance?
Neurocrine Biosciences (NBIX) reported strong Q2 2026 results and raised full-year INGREZZA sales guidance, yet its share price declined by about 10% on the day of the announcement, despite positive longer-term momentum. The stock is currently valued at $166.80, considered 13.5% undervalued by Simply Wall St's narrative fair value of $192.88, which is anchored in its rare disease and neurology portfolio and diversified CNS pipeline. However, its P/E ratio of 24x is slightly above the peer average, leading to mixed signals for investors.
Is Neurocrine Biosciences (NBIX) A Bargain After Strong Q2 Results And Higher Guidance?
Neurocrine Biosciences (NBIX) reported strong Q2 2026 results and raised full-year INGREZZA sales guidance, yet its share price saw a 10% decline. Despite this dip, the stock has shown positive long-term momentum with significant 90-day and 1-year returns. Simply Wall St's narrative suggests NBIX is undervalued, with a fair value of $192.88 against a current price of $166.80, driven by its diverse CNS pipeline and innovation in biologics.
Enterprise value to revenue forward of Neurocrine Biosciences, Inc. – SWB:NB3
This article provides financial information for Neurocrine Biosciences, Inc. (SWB:NB3) on TradingView, specifically focusing on its enterprise value to revenue forward metric. It details where to find this data within the platform's financial section. The content is primarily an informational stub for financial analysts or investors using TradingView.
Neurocrine Biosciences (NBIX) Stock Slides As Growth Spending Steals Focus
Neurocrine Biosciences (NBIX) stock dropped 10% despite strong Q2 2026 revenue and earnings, indicating the market is reacting to growth spending rather than current earnings. The company showed robust performance with INGREZZA and emerging products like CRENESSITY and VYKAT XR, but analysts are cautious about its heavy reliance on INGREZZA and potential future policy risks from drug pricing. Investors are advised to monitor the company's financial health and market valuation for potential entry points.
Neurocrine Biosciences (NBIX) Is Down 5.2% After Earnings Beat And Raised INGREZZA Outlook Has The Bull Case Changed?
Neurocrine Biosciences reported strong Q2 2026 earnings with revenue of US$959.0 million and net income of US$144.4 million, and raised its INGREZZA sales guidance. Despite these positive results, the stock fell 5.2%, reflecting ongoing concerns about pricing pressure and product concentration risks within its neurology portfolio. The company's future growth hinges on its ability to manage these market access challenges, even with strategic new hires in market access leadership.
Neurocrine Biosciences Q2 Earnings Call Highlights
Neurocrine Biosciences reported strong Q2 2026 revenues exceeding $950 million, a nearly 40% year-over-year increase, driven by INGREZZA and CRENESSITY sales, plus VYKAT XR's partial contribution. The company raised its full-year INGREZZA sales guidance and is integrating VYKAT XR following a $2.9 billion acquisition. Key Phase III pipeline data for osavampator and direclidine are anticipated in late 2027.
Neurocrine Biosciences Inc (NBIX) Shares Fall 10.1% -- What GF S
Neurocrine Biosciences Inc (NBIX) shares dropped 10.1% to $166.80, yet GuruFocus estimates the stock is undervalued with a GF Value™ of $192.59. The company holds a strong GF Score™ of 94/100, driven by excellent growth potential, but faces caution due to significant insider selling totaling $62.4 million in the last three months. Investors should weigh the potential for recovery and growth against the implications of insider activity and mixed guru sentiment.
Neurocrine Biosciences Slides as Q2 Results and Outlook Leave Little Room for Upside
Neurocrine Biosciences (NBIX) stock fell 10.0% following its Q2 2026 earnings release, which investors viewed as mixed rather than exceeding expectations. Despite solid demand for key products like INGREZZA, the company largely reaffirmed its existing outlook instead of raising guidance, leading to investor disappointment. This reaction was amplified by a strong pre-earnings run in the shares, indicating that investors were seeking a more significant catalyst.
Neurocrine Biosciences, Inc. Stock 12‑Month Price Target Raised to $209.63, Implies 13% Upside
Neurocrine Biosciences, Inc. (NBIX) has seen its average 12-month stock price target increased from $201.2 to $209.34 by 28 analysts, implying a potential 13% upside based on the July 30 closing price. The consensus rating among 31 covering analysts remains a "Buy," with 27 recommending Buy and 4 recommending Hold.
